MaxCyte, Inc. MaxCyte, Inc. - MXCR - Result of AGM

MaxCyte

31/10/2018 16:25

RNS Number : 9281F

MaxCyte, Inc.

31 October 2018

 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Result of AGM

 

Gaithersburg, MD - 31 October 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that at its Annual General Meeting held today at 11:00 EDT, all resolutions were duly passed.

 

 

For further information, please contact:

 

MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer
+1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Ryan McCarthy
Corporate Broking
James Stearns
+44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
Sukaina Virji
+44 (0)203 709 5700
maxcyte@consilium-comms.com

 

 

About MaxCyte

 

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END

 

 

RAGBLBDGDDXBGIB